No Data
Saint Noble Medical-B (02257.HK) will hold a Board of Directors meeting on March 27 to approve the annual performance.
Gelonghui, March 17th丨Saint诺医药-B (02257.HK) announced that the Board of Directors meeting will be held on March 27, 2025, to approve the release of the annual performance announcement of the company and its subsidiaries for the year ending December 31, 2024.
SIRNAOMICS-B: NOTICE OF BOARD MEETING
Saint Noble Pharmaceutical-B (02257): Cheng Hai has been appointed as a member of the Audit Committee.
Saint Noble Pharmaceuticals-B (02257) announced that Chang Hai has been appointed as the independent non-executive Director of the company to review...
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
Express News | Sirnaomics Ltd - Monin Ung Appointed as Chairlady
Press Release: Sirnaomics Promotes Francois Lebel, M.D. to Chief Medical Officer
